CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity
Menu
CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity
CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise.
CinRx Pharma announced today that Gavin Samuels, M.D., M.B.A has assumed the role of Chief Business Officer.
